SCHEMBL4490164

SCHEMBL4490164

CC(=O)NC(=O)Nc1cc[c]cc1

nearest known ligand 0.46

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
KMT2A Q03164 6/20 0.46
RAB9A P51151 6/20 0.46
NPC1 O15118 5/20 0.46
TAAR1 Q96RJ0 2/20 0.46
EPHX1 P07099 5/20 0.43
SMN1; SMN2 Q16637 7/20 0.42
HTT P42858 2/20 0.42
L3MBTL1 Q9Y468 1/20 0.42
NAPRT Q6XQN6 1/20 0.42
HSD17B10 Q99714 1/20 0.42
MEN1 O00255 5/20 0.42
MAPT P10636 4/20 0.41
TSHR P16473 2/20 0.41
ALDH1A1 P00352 2/20 0.41
TDP1 Q9NUW8 1/20 0.41
CA12 O43570 1/20 0.41
BRD4 O60885 1/20 0.41
NR1I2 O75469 1/20 0.41
CA1 P00915 1/20 0.41
CA2 P00918 1/20 0.41

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL19602 0.83 SMN1; SMN2 (0.60) KMT2ARAB9ANPC1TAAR1SMN1; SMN2
SCHEMBL28349149 0.81 SMN1; SMN2 (0.58) KMT2ARAB9ANPC1TAAR1SMN1; SMN2
SCHEMBL27742196 0.81 SMN1; SMN2 (0.58) KMT2ARAB9ANPC1TAAR1SMN1; SMN2
SCHEMBL2887905 0.79 NPC1 (0.70) KMT2ARAB9ANPC1TAAR1EPHX1
SCHEMBL745458 0.79 ALDH1A1 (0.59) KMT2ARAB9ANPC1TAAR1EPHX1
SCHEMBL6990986 0.78 NPC1 (0.44) KMT2ARAB9ANPC1TAAR1EPHX1
SCHEMBL751586 0.75 SMN1; SMN2 (0.74) KMT2ARAB9ANPC1TAAR1EPHX1
SCHEMBL1448293 0.74 CA12 (0.56) KMT2ARAB9ASMN1; SMN2HSD17B10MEN1
SCHEMBL751975 0.74 MTNR1B (0.47) KMT2ARAB9ANPC1EPHX1SMN1; SMN2
SCHEMBL779875 0.74 RAB9A (0.50) KMT2ARAB9ANPC1SMN1; SMN2MEN1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7511065-B2 Mixed lineage kinase modulators ELI LILLY AND COMPANY (US) 2009-03-31 US disclosed
US-20080113977-A1 Mixed Lineage Kinase Modulators ELI LILLY AND COMPANY 2008-05-15 US disclosed
EP-1567528-A1 MIXED LINEAGE KINASE MODULATORS ELI LILLY AND COMPANY (US) 2005-08-31 EP disclosed
WO-2004048383-A1 MIXED LINEAGE KINASE MODULATORS ELI LILLY AND COMPANY (US) 2004-06-10 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20080113977-A1 Mixed Lineage Kinase Modulators MYLK2, CSNK1G2, CSNK1A1 KMT2A 1757/4885RAB9A 1942/4885NPC1 2787/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.